BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35119702)

  • 1. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
    Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
    Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
    Mifsud W; Furtwängler R; Vokuhl C; D'Hooghe E; Pritchard-Jones K; Graf N; Vujanić GM
    Eur J Cancer; 2022 May; 166():1-7. PubMed ID: 35255331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplasia in Wilms tumor: A critical review.
    Vujanić GM; Mifsud W
    Pediatr Blood Cancer; 2024 Apr; ():e31000. PubMed ID: 38605554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
    Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
    Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
    Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
    Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies (2001-2020).
    D'Hooghe E; Furtwängler R; Chowdhury T; Vokuhl C; Al-Saadi R; Pritchard-Jones K; Graf N; Vujanić GM
    Cancer; 2023 Jun; 129(12):1930-1938. PubMed ID: 36929497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
    Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
    Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
    Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
    Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
    Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
    Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
    van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
    Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
    J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botryoid Wilms tumor: a non-existent "entity" causing diagnostic and staging difficulties.
    Vujanić GM; Schiavo Lena M; Sebire NJ
    Virchows Arch; 2019 Feb; 474(2):227-234. PubMed ID: 30515564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534).
    Chintagumpala MM; Perlman EJ; Tornwall B; Chi YY; Kim Y; Hoffer FA; Kalapurakal JA; Warwick AB; Shamberger RC; Khanna G; Hamilton TE; Gow KW; Paulino AC; Gratias EJ; Mullen EA; Geller JI; Fernandez CV; Ritchey ML; Grundy PE; Dome JS; Ehrlich PF
    Cancer; 2022 Jul; 128(13):2493-2503. PubMed ID: 35383900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
    Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
    Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
    Salama A; Kamel A
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.